Simplify Logo

Full-Time

Associate Scientist

Platform Technology

Confirmed live in the last 24 hours

Editas Medicine

Editas Medicine

201-500 employees

Develops gene editing treatments using CRISPR

Biotechnology
Healthcare

Mid, Senior

Cambridge, MA, USA

Category
Computational Biology
Genomics
Biology & Biotech
Required Skills
Tableau
Data Analysis
Requirements
  • B.S. in cell biology, or related field with 5+ years of relevant experience in industry; or M.S. in cell or molecular biology with 2+ years of relevant experience in industry
  • Independently design and run screening experiments, extract gDNA, submit for sequencing, analyze, and present data
  • Experience with mammalian cell culture, including immortalized and primary cells (ex. Liver Cells and HSCs)
  • Proficient in executing and analyzing functional assays including flow cytometry and western blots
  • Experience working with different screening modalities such as guide RNAs and LNPs and knowing how to formulate both RNP and LNPs
  • Experience with data analysis software such as PRISM, Tableau, and FlowJo
  • Familiar in molecular biology analyses such as qPCR and ddPCR
  • Familiar working with lab automation including both liquid handling robots (Biomek I7s, Mantis, Echo) and plate readers (Envision)
  • Excellent communication and interpersonal skills fostering effective teamwork
Responsibilities
  • Lead guide design, screening and selection of lead guide using editing and/or function assays for internal and external partner programs
  • Analyze and summarize screening results into proper documentation (ELN, Study Reports)
  • Implementation of a high-through LNP screening workflow, including automated LNP-formulations
  • Assist with RNP complexation and perform QC for internal program use

Editas Medicine focuses on gene editing using CRISPR technology, which allows for precise modifications to DNA in cells. This technique has the potential to correct genetic defects that lead to various diseases. The company is engaged in the entire process of drug development, from discovering new treatments to manufacturing and bringing them to market. Editas Medicine aims to create long-lasting therapies that can greatly enhance the quality of life for patients suffering from serious illnesses. Unlike many competitors, Editas has a diverse pipeline of experimental medicines and actively shares clinical data to keep stakeholders informed. The ultimate goal is to provide effective treatments for patients worldwide, while also generating revenue through partnerships and commercialization of their genomic medicines.

Company Stage

IPO

Total Funding

$884.6M

Headquarters

Cambridge, Massachusetts

Founded

2013

Growth & Insights
Headcount

6 month growth

17%

1 year growth

23%

2 year growth

17%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful clinical trials, like the EDIT-101 for Leber Congenital Amaurosis, demonstrate the potential for groundbreaking treatments.
  • The extension of collaborations with major pharmaceutical companies like Bristol Myers Squibb indicates strong industry validation and potential for future growth.
  • Recent investments, such as the $23.36 million from Marshall Wace LLP, reflect confidence in the company's innovative approach and financial stability.

What critics are saying

  • The highly competitive field of gene editing requires continuous innovation to maintain a leading position.
  • Regulatory hurdles and ethical concerns surrounding gene editing could delay or impede the commercialization of treatments.

What makes Editas Medicine unique

  • Editas Medicine leverages CRISPR technology to develop transformative treatments for serious diseases, setting it apart from traditional biotech firms.
  • The company's comprehensive approach, from discovery to commercialization, ensures a streamlined process for bringing genomic medicines to market.
  • Editas Medicine's strategic partnerships, such as with Bristol Myers Squibb, enhance its capabilities in developing gene-edited therapies.

Help us improve and share your feedback! Did you find this helpful?